Marbofloxacin

Cas No.:	115550-35-1
Chemical Name:	Marbofloxacin
Synonyms:	Marbofloxacin;9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-piperazino)-7-oxo-7h-pyrido[1,2,3-ij][1,2,4]benzoxadiazine-6-carboxylic acid;9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid;Marbocyl;Marbofloxacin (INN);Marbofloxacino [INN-Spanish];UNII-8X09WU898T;Zeniquin;Zeniquin®;9-Fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic Acid;ZENIQUIN(R);Marbofloxacine;Marbofloxacin, Vetranal;Marbofloxacin Solution, 100ppm;Marbofloxacin Solution, 1000ppm;o-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-;Marbofloxacine [INN-French];Marbofloxacinum [INN-Latin];BPFYOAJNDMUVBL-UHFFFAOYSA-N;8X09WU898T;AK327608;DSSTox_CID_26600;DSSTox_RID_81755;DSSTox_GSID_46600;7H-Pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methy
SMILES:	CN1CCN(CC1)C2=C3C4=C(C=C2F)C(=O)C(C(O)=O)=CN4N(C)CO3
Formula:	C17H19FN4O4
M.Wt:	362.3556
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Marbofloxacin is a potent antibiotic of which depends upon its inhibition of DNA-gyrase. Marbofloxacin is a synthetic, broad spectrum bactericidal agent.Marbofloxacin is a third-generation fluoroquinolone for veterinary use, the antimicrobial of which depends upon its inhibition of DNA-gyrase and topoisomerase IV. With a broad spectrum bactericidal activity and good efficacy, marbofloxacin is indicated for dermatological, respiratory and urinary tract infections due to both Gram-positive and Gram-negative bacteria and Mycoplasma [1].Administration of Marbofloxacin at 6 mg/kg once daily for 7 days in a Staphylococcus aureus infection in tissue cages in ponies is not effective for the elimination of S. aureus infections from secluded sites [2]. The pharmacokinetic properties of marbofloxacin were investigated in 6 horses after i.v., subcutaneous and oral administration of a single dose of 2 mg/kg bwt and the minimal inhibitory concentrations (MIC) assessed for bacteria isolated from equine infectious pathologies. The clearance of marbofloxacin was mean +/- s.d. 0.25 +/- 0.05 l/kg/h and the terminal half-life 756 +/- 1.99 h. The marbofloxacin absolute bioavailabilities after subcutaneous and oral administration were 98 +/- 11% and 62 +/- 8%, respectively. Considering the breakpoint values of efficacy indices for fluoroquinolones, a marbofloxacin dosage regimen of 2 mg/kg bwt/24 h by i.v., subcutaneous or oral routes was more appropriate for enterobacteriaceae than for S. aureus [3]. Toxicity: cramps; vomiting; anorexia; soft stools; diarrhoea
Target:	DNA-gyrase
References:	[1]. Shen J, et al. Marbofloxacin. Acta Crystallogr Sect E Struct Rep Online. 2012 Apr 1;68(Pt 4):o998-9. [2]. Voermans M, et al. Clinical efficacy of intravenous administration of marbofloxacin in a Staphylococcus aureus infection in tissue cages in ponies. J Vet Pharmacol Ther. 2006 Dec;29(6):555-60. [3]. Bousquet-Melou A, et al. Pharmacokinetics of marbofloxacin in horses. Equine Vet J. 2002 Jul;34(4):366-72.